Type
Internal restructuring
Country
United Kingdom
Region
North West; Merseyside; Liverpool
Location of affected unit(s)
Speke
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

140 jobs
Number of planned job losses
Job loss
Announcement Date
11 January 2017
Employment effect (start)
Foreseen end date

Description

Elanco Animal Products, a factory on Merseyside, has announced the loss of 140 jobs. The company, which is a division of the pharmaceutical company Eil Lilly, mainly manufactures products which treat diseases among farm animals. A spokesperson commented that the decision was taken after reviewing global conditions and was not reflective of the performance of the workforce on Merseyside. The spokesperson also stressed that the company intends to keep the site open. A voluntary redundancy scheme will operate for permanent staff and arrangements with contractors will be reviewed. A statutory 45 day consultation period is expected to conclude in March 2017.


Sources

  • 11 January 2017: Liverpool Echo

Citation

Eurofound (2017), Elanco Animal Health , Internal restructuring in United Kingdom, factsheet number 89781, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/89781.